Innate Pharma SA

Innate Pharma SA (IPHA) has logged zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating stable operational footing in our near-term monitoring window. However, low signal in a 90-day snapshot does not preclude material risk; clinical-stage biotech firms face persistent dilution and financing pressures that operate on longer cycles. The full $49 Report extends analysis to 12 months of 8-K context, maps the complete financing history, calculates dilution risk scores, and flags AI-detected early warnings across officer changes and regulatory shifts. The full $49 Report adds the historical and forward-looking risk layers that 90-day stability cannot capture.